

أ.د. طارق أبو الفضل
سيرة ذاتية

	الاسم	أ.د. طارق أبو الفضل محمد حسن
	Name	Tarek Aboul-Fadl Mohamed Hassan
	الاسم المستخدم في النشر العلمي	Tarek Aboul-Fadl
	الوظيفة الحالية وجهة العمل	أستاذ الكيمياء الدوائية المتفرغ بكلية الصيدلة - جامعة أسيوط
	الدرجة العلمية (اسم الجامعة والدولة)	أستاذ دكتور بكلية الصيدلة – جامعة أسيوط- مصر
التخصص العام (General Specialization)		كيمياء صيدلانية
التخصص الدقيق (Specific Specialization)		كيمياء دوائية
البريد الإلكتروني		Fadl@aun.edu.eg
ملخص السيرة الذاتية المؤهلات الدراسية:		
<p>1. دكتوراه الفلسفة في العلوم الصيدلانية (كيمياء صيدلانية طبية) في تشييد ودراسة مشتقات من محتلات ن⁴ - سيراابن كأدوية كامنة -يناير ١٩٩٤ - جامعة أسيوط (في إطار نظام القنوت ونظام الإشراف المشترك بين جامعة أسيوط وجامعة جوزاي / اليابان).</p> <p>2. ماجستير العلوم الصيدلانية (كيمياء صيدلانية) في تشييد بعض مشتقات البيرازول ذات صفات مخلبية تفيد في التأثيرات البيولوجية -نوفمبر ١٩٨٩ / جامعة أسيوط</p> <p>3. بكالوريوس العلوم الصيدلانية بتقدير عام جيد جدا مع مرتبة الشرف - يونيو ١٩٨٤ / جامعة أسيوط</p> <p>التدرج العلمي والوظيفي:</p> <p>1. أستاذ متفرغ إعتباراً من 31 أغسطس 2021 إلى الآن (قسم الكيمياء الدوائية - كلية الصيدلة / جامعة أسيوط - مصر)</p> <p>2. أستاذ إعتباراً من ٢٥ يوليو ٢٠٠٤ - 30 أغسطس 2021 (قسم الكيمياء الدوائية - كلية الصيدلة / جامعة أسيوط - مصر)</p> <p>3. أستاذ مساعد إعتباراً من ٣٠ مايو ١٩٩٩ - ٢٤ يوليو ٢٠٠٤ (قسم الكيمياء الصيدلانية الطبية - كلية الصيدلة / جامعة أسيوط - مصر)</p> <p>4. مدرس إعتباراً من ٢٠ فبراير ١٩٩٤ - ٢٩ مايو ١٩٩٩ (قسم الكيمياء الصيدلانية الطبية - كلية الصيدلة / جامعة أسيوط - مصر)</p> <p>5. مدرس مساعد إعتباراً من ٣ ديسمبر ١٩٨٩ - ١٩ فبراير ١٩٩٤ (قسم الكيمياء الصيدلانية - كلية الصيدلة / جامعة أسيوط).</p> <p>6. معيد إعتباراً من ١٤ أكتوبر - ٢ ديسمبر ١٩٨٩ (قسم الكيمياء الصيدلانية - كلية الصيدلة / جامعة أسيوط)</p> <p>المناصب الإدارية:</p> <p>1. وكيل الكلية لشئون التعليم والطلاب إعتباراً من ٣٠ أكتوبر 2013 - 29 أكتوبر 2016</p> <p>2. رئيس مجلس قسم الكيمياء الدوائية إعتباراً من 17 سبتمبر 2019 - 30 أغسطس 2021.</p> <p>البعثات الدراسية والمهام العلمية:</p> <p>1. عالم زائر بمعهد الصيدلة والكيمياء الغذائية - جامعة فريدريش ليكسندر- نورنبرج / إيرلانجن - ألمانيا - أغسطس 2013 - نوفمبر 2013</p> <p>2. أستاذ زائر بقسم الكيمياء الصيدلانية - كلية الصيدلة / جامعة الملك سعود - الرياض - المملكة العربية السعودية من ٢٢ أغسطس ٢٠٠٥ حتى ٢٠ يونيو ٢٠١٢</p> <p>3. باحث زائر بقسم الكيمياء الطبية - كلية الصيدلة / جامعة يوتا - الولايات المتحدة الأمريكية - فبراير ٢٠٠٤ - أغسطس ٢٠٠٥</p> <p>4. باحث زائر بقسم الكيمياء الطبية - كلية الصيدلة / جامعة يوتا - الولايات المتحدة الأمريكية - مايو ٢٠٠١ - نوفمبر ٢٠٠٢</p> <p>5. باحث زائر بمعهد الصيدلة والكيمياء الغذائية - جامعة نورنبرج / إيرلانجن - ألمانيا - سبتمبر ١٩٩٩ - ديسمبر ١٩٩٩</p> <p>6. باحث زائر بمعهد الكيمياء الصيدلانية - جامعة فيينا/ النمسا - ديسمبر ١٩٩٧ - أغسطس ١٩٩٨</p> <p>7. عضو بعثة دراسية بقسم الكيمياء التكنوصيدلانية - كلية الصيدلانية - جامعة جوساي/ اليابان - مايو ١٩٩١ - أغسطس ١٩٩٣</p>		

أ.د. طارق أبو الفضل سيرة ذاتية

الجوائز العلمية:

- جائزة الشركة العربية للصناعات الدوائية والمستلزمات الطبية "أكديما" لأحسن بحث علمي في الوطن العربي لعام 2013
- درع كلية الصيدلة - جامعة أسيوط
- درع جامعة أسيوط
- درع محافظة أسيوط
- درع نقابة صيدلة مصر
- درع نقابة صيدلة أسيوط

النشر العلمي:

- واحد وثمانون بحثاً منشوراً في دوريات علمية دولية ومحلية محكمة
- ثلاث وخمسون بحثاً منشوراً في مؤتمرات علمية محلية ودولية (القوائم في نهاية السيرة الذاتية ومفصلة في الموقع على شبكة المعلومات)
- عدد مرات الإستشهاد : 2262 (2024/6/29) معامل هيرش (H index) : 26 Google Scholar
- عدد مرات الإستشهاد : 1621 (2024/6/29) معامل هيرش (H index) : 23 Scopus
- مدرج في قائمة أفضل 2% من العلماء الأكثر تميزاً عالمياً عن مجمل الأعمال (قائمة جامعة ستانفورد الأمريكية لعام 2023)

Greysen, S. Ryan	University of Pennsylvan usa	97	2009	2023
Feng, Guoqiang	Central China Normal Un chn	104	2000	2023
Hengartner, Urs	David R. Cheriton School can	69	1999	2023
Aboul-Fadl, Tarek	Faculty of Pharmacy egypt	75	1993	2023
Tarleton, Steve	Loughborough University gbr	63	1986	2016
Leary, Julie	University of California, usa	167	1983	2017
Stanish, Charles	University of South Flori usa	37	1989	2022

<https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/6?fbclid=IwAR3Dhg8Z6kVKbqHJMMG-zIsjip-XX2wiNKPt8Vs0ksozOBMw74qZFfZJSQk>

عضوية الجمعيات العلمية الدولية واللجان:

1. لجنة أخلاقيات البحث بكلية الصيدلة ، جامعة أسيوط / مصر ، أبريل 2024 حتى الآن
2. لجنة أخلاقيات البحث بمعهد أبحاث ودراسات البيولوجيا الجزيئية ، جامعة أسيوط / مصر ، أكتوبر 2020 حتى الآن
3. عضو مجلس بحوث الدواء بأكاديمية البحث العلمي والتكنولوجيا إعتباراً من مايو 2018 وحتى الآن
4. عضو هيئة تحرير للعديد من دوريات علمية عالمية (مفصلة في الموقع على شبكة المعلومات)
5. محكم للعديد من الدوريات العلمية العالمية ومراكز البحوث والجامعات العربية (مفصلة في الموقع على شبكة المعلومات)
6. محكم للجنة العلمية الدائمة لترقية الأساتذة والأساتذة المساعدين /المجلس الأعلى للجامعات/ مصر وجامعة الإسراء بالأردن وجامعة أم القرى بالمملكة العربية السعودية.
7. شراكة دحر السل - الفريق العامل المعني بتطوير أدوية جديدة للسل منذ فبراير ٢٠١٠ حتى الآن.
8. الجمعية الأمريكية للكيمياء منذ يناير ٢٠٠٢ و حتى الآن.
9. الجمعية الصيدلانية المصرية منذ مايو ١٩٩٤ وحتى الآن.

براءات الاختراع:

خمس براءات إختراع دولية مسجلة (القائمة في نهاية السيرة الذاتية ومفصلة في الموقع على شبكة المعلومات)

المشروعات البحثية

1. باحث في مشروع " خارطة طريق" استراتيجية متكاملة نحو تصنيع الخامات الدوائية الفعالة وغير الفعالة في مصر "" والممول من أكاديمية البحث العلمي و التكنولوجيا (ميزانية 200.000 جنيه مصرى) مارس 2023 - فبراير 2024.
2. باحث في مشروع " خارطة الطريق لتنمية صناعة الدواء في مصر" والممول من أكاديمية البحث العلمي و التكنولوجيا (ميزانية 220.000 جنيه مصرى) يونيو - ديسمبر 2019.

أ.د. طارق أبو الفضل
سيرة ذاتية

3. باحث رئيس في مشروع مثبطات تشييدية مبتكرة للخلايا اليوزينية ذات فاعلية محتملة ضد اليربو والممول من صندوق العلوم والتنمية التكنولوجية STDF، (ميزانية مليون جنيه مصرى) 2016 - 2018 .
4. باحث رئيس في مشروع تصميم وتشيد منظومة توافقية لبعض قواعد شيف من مشتقات الإندولين -٢ و٣-دايون ذات فاعلية محتملة كمضادات للدردن والممول من برنامج الخطة الوطنية(مدينة الملك عبدالعزيز للعلوم والتقنية ، ميزانية 1.5 مليون ريال سعودي) ٢٠09 - 2011 .
5. باحث في مشروع ابتكار جساسات نانوية تعتمد على الكيمياء المناعية لقياس دلالات السرطان في العينات البيولوجية والممول من برنامج الخطة الوطنية(مدينة الملك عبدالعزيز للعلوم والتقنية ، ميزانية 1.3 مليون ريال سعودي) ٢٠10 - 2012 .
6. باحث في مشروع تشيد مشتقات رباعي هيدرو - ٢يد - ١،٣،٥ - ثياديازين-٢- ثيون لبعض أحماض أمينية غير طبيعية ذات فاعلية محتملة كمضادات ميكروبية والممول من مركز بحوث كلية الصيدلة - جامعة الملك سعود، ٢٠٠٩ - ٢٠١٠ .
7. باحث رئيس في مشروع دراسة إستقلاب (أيض) بعض الحيوانات الغريبة بالبكتريا المعوية الإنسانية خارج الجسم والممول من مركز بحوث كلية الصيدلة- جامعة الملك سعود، ٢٠٠٧-2009 .
8. باحث رئيس في مشروع تشيد وإختبار منظومة التوصيل التفاضلي للكبد لعقار الأمتادين لزيادة فاعليته ضد الفيروس الكبدى الوبائى ج والممول من مركز بحوث كلية الصيدلة - جامعة الملك سعود، ٢٠٠٦ - ٢٠٠٨ .
9. باحث في مشروع تشيد ودراسة بعض مشتقات السيلينيوم ذات الفاعلية الوقائية المحتملة ضد السرطان والممول من مركز بحوث كلية الصيدلة - جامعة الملك سعود، ٢٠٠٦ - ٢٠٠٨ .
10. باحث في مشروع إبتكار طريقة بديلة غير معتاده لتشيد مرادفات نقيه فراغيا لمركبات ٤- مستبدلات-ن-اريل سلفونيل - ٢- أميدازوليدينون واختبارها كمضادات لأمراض السرطان مع دراستها بواسطة النماذج الجزيئية والممول من مركز بحوث كلية الصيدلة - جامعة الملك سعود، ٢٠٠٦ - 2008 .
11. باحث في مشروع ابتكار طرق تحليل مناعية حساسة لتعيين مادة 2- ديوكسى سيتيدين فى البلازما للدلالة المبكرة على استجابة مرضى سرطان الثدى للعلاج الكيماوى والممول من مركز بحوث كلية الصيدلة - جامعة الملك سعود ، 2006 - 2007 .
12. باحث في مشروع تشيد وإختبار منظمات الخلايا الإيزوفيلية كعلاجات للربو بالإشتراك مع قسم الأمراض الجلدية والمناعية -جامعة يوتا الأمريكية و الممول من نفس الجامعة الفترة من أكتوبر ٢٠٠٤ حتى ١ أغسطس ٢٠٠٥ .
13. باحث في مشروع تشيد بعض مشتقات السيلينيوم كوقائيات للسرطان بالإشتراك مع قسم الكيمياء الطبية - جامعة يوتا و الممول من معهد الصحة القومى الأمريكى (NIH) فى الفترة من ٥ فبراير ٢٠٠٤ حتى ١ أغسطس ٢٠٠٥ .
14. باحث في مشروع تشيد بوليمرات نيكولوتيدية ونيكلوببتيدية متجانسة كمضادات لفيروس نقص المناعة الأدمى (HIV) بالإشتراك مع قسم الكيمياء الطبية - جامعة يوتا و الممول من معهد الصحة القومى الأمريكى (NIH) فى الفترة من ١ مايو ٢٠٠١ إلى ١ نوفمبر ٢٠٠٢ .
15. باحث في مشروع تصميم وتشيد مترابطات إنتقائية لمستقبلات الدوبامين) د ٤ بالإشتراك مع معهد الكيمياء الصيدلانية - جامعة إيرلانجن - ألمانيا و الممول من هيئة التعاون العلمى الألمانية (DAAD) فى الفترة من ١٤ سبتمبر ١٩٩٩ إلى ٥ ديسمبر ١٩٩٩ .

16. باحث في مشروع تشييد نظيرات المضاد الحيوى حمض الهيبتليديك (Heptelidic Acid) بالإشتراك مع معهد الكيمياء الصيدلية - جامعة فيينا و الممول من هيئة التعاون العلمى النمساوية (FWF) فى الفترة من ٥ ديسمبر ١٩٩٧ إلى ٣١ يوليو

١٩٩٨

المواقع على شبكة المعلومات:

<https://www.aun.edu.eg/pharmacy/ar/tarek-aboul-fadl-mohammad-hassan>

[Scopus preview - Aboul-Fadl, Tarek - Author details - Scopus](#)

<http://scholar.google.com.eg/citations?user=e2ALmfAAAAAJ&hl=en>

https://www.researchgate.net/profile/Tarek_Aboul-Fadl2

<https://orcid.org/0000-0002-1963-4332>

<https://www.linkedin.com/in/tarek-aboul-fadl-ba904032/>

<https://www.facebook.com/tarek.aboulfadl>

قوائم النشر العلمى وبراءات الإختراع:

1. براءات الإختراع

1. Wagner, L.A., Szardenings, K., Gleich, G. J., **Hassan, T.A.M.** (2007): Methods and Compositions Related to Eosinophil Regulation. WO 2007/136707 A3. Nov. 19 2007.
2. Franklin, M.R., Roberts, J., **Aboul-Fadl, T.** (2008): Prodrugs and Conjugates of Thiol-and Selenol-Containing Compounds and Methods of Use Thereof. Pat. No.: US 7,425,635 B2. Sep. 16 2008.
3. Wagner, L.A., Szardenings, K., Gleich, G. J., **Mohamed, T.A.** (2010): Methods and Compositions Related to Eosinophil Regulation. Pat. No.: US 2010/0016410 A1. Jan. 21 2010.
4. **Hassan, T. A. M.**, Kadi, A.A., Abdel-Aziz, H.A. (2012): Novel N,N'-Hydrazino-bis-isatin Derivatives with Selective Activity Against Multidrug-Resistant Cancer Cells. Pat. No.: US 2012/0252860 A1. Oct. 4 2012.
5. **Hassan, T. A. M.**, Bin Jubair, F. A. S. (2012): Isatin Derivatives, Medicaments containing the Isatin Derivatives and Methods for its Preparation. Pat. No.: US 2012/0259119860 A1. Oct. 11 2012.
6. **Hassan, T. A. M.**, Bin Jubair, F. A. S. (2013): Isatin Derivatives, Medicaments containing the Isatin Derivatives and Methods for its Preparation. Pat. No.: US 2013/ US 8552026 B2. Oct. 8 2013.
7. **Hassan, T. A. M.**, Kadi, A.A., Abdel-Aziz, H.A. (2013): Novel N,N'-Hydrazino-bis-isatin Derivatives with Selective Activity Against Multidrug-Resistant Cancer Cells. Pat. No.: US 8,497,296 B2. Jul. 30, 2013.
8. **Hassan, T. A. M.**, Al-Hamad, S. S., Al-Obaid, A., Piazza, G. A. (2016): Amide Amino Acid Esters of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) as Potent Inhibitors of Tumor Cell Growth. Pat. No. EP 2 623 098 B1. . Jul. 7, 2016.

2. الكتب وفصول الكتب

1. Ashraf M. Mahmoud, Nasr Y. Khalil, Ibrahim A. Darwish, Tarek Aboul-Fadl, Selective Spectrophotometric and Spectrofluorometric Methods for the Determination of Amantadine Hydrochloride in Capsules and Plasma via Derivatization with 1,2-Naphthoquinone-4-sulphonate, in Analytical Chemistry. Methods and Applications, Harold H. Trimm (Ed), Apple Academic Press, 1st edition pp 46-62 (2011). ISBN 9780429098369. <https://doi.org/10.1201/b12872>
2. Roadmap for the Development of Drug Industry in Egypt, Academy for Science & Technology, Mansoura University Press (2020). ISBN: 9789772687626, Egyptian ISBN: 2020/20436.

1. Computational Design of Azine-Linked Hybrids of 2-Indolinone-Thiazolodine Scaffold as Novel and Promising Quorum Sensing Inhibitors, Wesam S. Qayed, Mostafa A. Hassan, Ahmed Megahed Abouwarda, Yasser Musa Ibrahim & **Tarek Aboul-Fadl**, Polycyclic Aromatic Compounds, **44**(1), 1-24(2024), DOI: [10.1080/10406638.2023.2165511](https://doi.org/10.1080/10406638.2023.2165511)
2. Effects of lidocaine derived organic compounds on eosinophil activation and survival, Seung-Heon Shin, Mi-Kyung Ye, Mi-Hyun Chae, Ahmed S. Aboaraia, Abu-Baker M Abdel-Aal, Wesam S. Qayed, Hend A.A. Abd El-wahab, Ola F. Abou-Ghadir and **Tarek Aboul-Fadl**, molecules, **28**(15), 5696(2023). <https://doi.org/10.3390/molecules28155696>
3. Novel Azine Linked Hybrids of 2-Indolinone and Thiazolodinone Scaffolds as CDK2 inhibitors with potential anticancer activity: In Silico Design, Synthesis, Biological, Molecular Dynamics and Binding Free Energy Studies, Wesam S. Qayed, Mostafa A. Hassan, Wael M. El-Sayed, José Rogério A. Silva, **Tarek Aboul-Fadl**, Bioorganic Chemistry, **126**, 105884(2022). <https://doi.org/10.1016/j.bioorg.2022.105884>
4. New Cell Cycle Checkpoint Pathways Regulators with 2-Oxo-indoline Scaffold as Potential Anticancer Agents: Design, Synthesis, Biological Activities and *In Silico* Studies, Hend A.A. Abd El-wahab, Hany S. Mansour, Ahmed M. Ali, Raafat El-Awady, **Tarek Aboul-Fadl**, Bioorganic Chemistry, **120**, 105622(2022). <https://doi.org/10.1016/j.bioorg.2022.105622>
5. Crystal structure and quantum chemical calculations of (E)-1-benzyl-3-((4-methoxyphenyl)imino)-5-methylindolin-2-one, H. A.A. Abdel El-wahab, A. K. Hamdy, C. Schulzke, **T. Aboul-Fadl**, W.S. Qayed, Journal of Heterocyclic Chemistry, **58**(8), 1601-1609 (2021). DOI: <https://doi.org/10.1002/jhet.4284>
6. Inversion Kinetics of Some *E/Z* 3-(Benzylidene)-2-Oxo-indoline Derivatives and Their *In Silico* CDK2 Docking Studies, Hany S. Mansour, Hend A.A. Abd El-Wahab, Ahmed M. Ali, **Tarek Aboul-Fadl**, RSC Advances, **11**, 7839 - 7850 (2021). DOI: <https://doi.org/10.1039/D0RA10672K>
7. Design and Synthesis of Novel Isatin-Based derivatives Targeting Cell Cycle Checkpoint Pathways as Potential Anticancer Agents, Mohamed A. Yousef, Ahmed M. Ali, Wael M. El-Sayed, Wesam S. Quayed, Hassan H. A. Farag and **Tarek Aboul-Fadl**, Bioorganic Chemistry, **105**, 104366 (2020). <https://doi.org/10.1016/j.bioorg.2020.104366>
8. Pharmacokinetic studies of naproxen amides of some amino acid esters with promising colorectal cancer chemopreventive activity, **Tarek Aboul-Fadl**, Soliman S. Al-Hamad, Ehab A. Fouad, Bioorganic Chemistry, **76**, 370-379 (2018). <https://doi.org/10.1016/j.bioorg.2017.12.006> (<https://authors.elsevier.com/a/1WGGQAHs8INQK>)
9. Synthesis, characterization and pharmacological evaluation of certain enzymatically cleavable NSAIDs amide prodrugs, Tilal Elsaman, Omar A.A. Aldeeb, **Tarek Aboul-Fadl**, Elnazeer I. Hamedelneil, Bioorganic Chemistry, **70**, 144-152(2017). <http://dx.doi.org/10.1016/j.bioorg.2016.12.005>
10. Synthesis and anti-mycobacterial activity of 4-(4-phenyl-1H-1,2,3-triazol-1-yl)salicylhydrazones: revitalizing an old drug, Hajjaj H. M. Abdu-Allah, Bahaa G. M. Youssif, Mostafa H. Abdelrahman, Mohammed K. Abdel-Hamid, Rudraraju S. Reshma, Perumal Yogeeswari, **Tarek Aboul-Fadl**, Dharmarajan Sriram, Archives of Pharmacal Research, **40**(2), 168-179 (2017). DOI: [10.1007/s12272-016-0882-x](https://doi.org/10.1007/s12272-016-0882-x)
11. Synthesis, Characterization and Antiproliferative Activity of Certain Meclofenamic Acid Amides, Tilal Elsaman, Omar A. Al-Deeb, **Tarek Aboul-Fadl**. Asian Journal of Chemistry, **29**(2), 291-295 (2017). <https://doi.org/10.14233/ajchem.2017.20165>.

12. Synthesis and antiproliferative activity of some novel amides of flufenamic acid and diclofenac, Tilal Elsaman, Omar A. A. Aldeeb, **Tarek Aboul-Fadl** and Abdullah Al-Dhfyhan. *Der Pharma Chemica*, **8(2)**, 434-443 (2016).
13. Schiff Bases of Indoline-2,3-dione (Isatin) Derivatives as Efficient Agents Against Resistant Strains of *Mycobacterium tuberculosis*, **Tarek Aboul-Fadl**, Mohammed K. Abdel-Hamid and Adel F. Youssef. *Der Pharma Chemica*, **7(8)**, 217-225 (2015).
14. Synthesis and in vitro evaluation of ferutinol aryl esters for estrogenic activity and affinity toward cannabinoid receptors, Ahmed M. Galal Osman, Ehab A. Abourashed, Desmond Slade, Safwat A. Ahmed, Waseem Gul, Shabana I. Khan, **Tarek Abo Elfadl**, Olivia R. Dale, Afeef S. Husni, Stephen J. Cutler, Mahmoud A. ElSohly. *Medicinal Chemistry Research*, **24(6)**, 2670-2678(2015). DOI: 10.1007/s00044-015-1319-7
15. Synthesis and Characterisation of *bis*-3,5-Disubstituted Thiadiazine-2-thione Derivatives as Anticancer Agents, A. A. Radwan, **Tarek Aboul-Fadl**, A. Al-Dhfyhan and W.M. Abdel-Mageed. *Asian Journal of Chemistry*, **26** (23), 8145-8150 (2014).
16. Novel non-cyclooxygenase inhibitors derivatives of naproxen for colorectal cancer chemoprevention, **Tarek Aboul-Fadl**, Suliman S. Al-Hamad, Kevin Lee, Nan Li, Bernard D. Gary, Adam B. Keeton, Gary A. Piazza and Mohammed K. Abdel-Hamid. *Medicinal Chemistry Research*, **23**, 4177-4188 (2014). DOI:10.1007/s00044-014-0979-z
17. Some New NSAIDs Prodrugs: An Efficient Synthesis, Spectral Characterization and X-ray Crystal Structure Studies, **Tarek Aboul-Fadl**, Tilal Elsaman, Omar A. Al-Deeb, Hazem A. Ghabbour, C. S. Chidan Kumar, Fun Hoong Kun. *Asian Journal of Chemistry*, **26**, 5249-5254 (2014). <http://dx.doi.org/10.14233/ajchem.2014.16949>
16. A Combined Experimental Green Flow-Injection Procedure and Computational Analysis to Determine Amino Acids, Samy Emara, **Tarek Aboul-Fadl**, Abdel Nasser El-Shorbagy, Maha Kamal, Walaa Zarad, Mohamed Abdel Kawi. *American Chemical Science Journal*, **3**, 419-433(2013). <http://www.sciencedomain.org/issue.php?iid=242&id=16>
17. A highly sensitive automated flow immunosensor based on kinetic exclusion analysis for determination of the cancer marker 8-hydroxy-2'-deoxyguanosine in urine. Ibrahim Ali Darwish, Tanveer A Wani, Nasr Khalil, **Tarek Aboul-Fadl**, Adnan Kadi and Abdul-Rahman Al-Majed. *Anal. Methods*, **5**, 1502-1509 (2013). DOI: 10.1039/C3AY26292H
18. Design, Synthesis and Pharmacophoric Model Building of Novel Substituted Nicotinic Acid Hydrazones with Potential Antiproliferative Activity. Hatem A. Abdel-Aziz, **Tarek Aboul-Fadl**, Abdul-Rahman M. Al-Obaid, Mohamed Ghazzali, Abdullah Al-Dhfyhan and Alessandro Contini. *Archives of Pharmacal Research*, **35**, 1543-1552 (2012).
19. Schiff bases of indoline-2,3-dione (isatin) with potential antiproliferative activity, **Tarek Aboul-Fadl**, Awwad A. Radwan, Mohamed Attia, Abdullah Al-Dhfyhan, Hatem A. Abdel-Aziz. *Chemistry Central Journal*, **6**, 49(2012). doi:10.1186/1752-153X-6-49.
20. Novel Schiff bases of indoline-2,3-dione and nalidixic acid hydrazide: synthesis, *in vitro* antimycobacterial and *in silico* mycobacterium tuberculosis (*mtb*) DNA gyrase inhibitory activity. **Tarek Aboul-Fadl**, Awwad A. Radwan, Hatem A. Abdel-Aziz, Mohd. Baseeruddin, Mohamad I. Attia and Adnan Kadi. *Digest Journal of Nanomaterials and Biostructures*, **7**, 329-338 (2012).
21. 3,5-Disubstituted Thiadiazine-2-thiones: A New Cell-Cycle Inhibitors. Awwad A. Radwan, Abdullah Al-Dhfyhan, Mohammed K. Abdel-Hamid, Abdullah A. Al-Badr and **Tarek Aboul-Fadl**. *Archives of Pharmacal Research*, **35**, 35-49(2012).
22. Amantadine Amides Prodrugs as Hepatic Delivery Systems to Enhance its Activity Against HCV. **Tarek Aboul-Fadl**, Mahmoud M. Sheha, Adel S. El-Azab, Hatem A. Abdel-Aziz. *Digest Journal of Nanomaterials and Biostructures*, **6**, 1675-1683(2011).

23. Schiff Bases of Indoline-2,3-Dione: Potential Novel Inhibitors of Mycobacterium Tuberculosis (Mtb) DNA Gyrase. **Tarek Aboul-Fadl**, Hatem A. Abdel-Aziz, Mohammed K. Abdel-Hamid, Tilal Elsaman, Jane Thanassi and Michael J. Pucci. *molecules*, **16**, 7864-7879 (2011).
24. (Z)-Ethyl 2-cyano-2-(2-(5,6-dimethyl-4-(thiophen-2-yl)-1H-pyrazolo[3,4-b]pyridin-3-yl)hydrazono)acetate. Hoong-Kun Fun, Madhukar Hemamalini, Hatem A. Abdel-Aziz and **Tarek Aboul-Fadl**. *Acta Crystallographica Section E*, **67**, o2145–o2146 (2011).
25. Microwave-Assisted Solution-Phase Synthesis and DART-Mass Spectrometric Monitoring of Combinatorial Library of Indolin-2,3-Dione Schiff Bases with Potential Antimycobacterial Activity. **Tarek Aboul-Fadl**, Hatem A. Abdel-Aziz, Adnan Kadi, Pervez Ahmad, Tilal Elsaman, Mohamed W. Attwa and Ibrahim A. Darwish. *molecules*, **16**, 5194-5206 (2011).
26. Microwave-assisted, One-step Synthesis of Fenamic Acid Hydrazides from Their Acids. **Tarek Aboul-Fadl**, Hatem A. Abdel-Aziz, Adnan Kadi, Ahmed Bari, Pervez Ahmad, Tilal Al-samani, Seik Weng Ng. *molecules*, **16**, 3544-3551 (2011).
27. Cell Screening Assay for Identifying Inhibitors of Eosinophil Proliferation. Jessica J. Kempe-Dustin, **Tarek Aboul-Fadl**, Clarissa Christensen, Robert Palais, Krishna Parsawar, Gerald J. Gleich, and Lori A. Wagner. *Drug Development Research*, **72**(4), 353-360 (2011).
28. (Z)-3Hydrazinylidene-1-phenylindolin-2-one. Hatem A. Abdel-Aziz, Ahmed Bari, **T. Aboul-Fadl** and Seik Weng Ng. *Acta Crystallographica Section E*, 66(Pt 11): o3014(2010).
29. Effects of Isatin-Isoniazid Derivatives on Drug Metabolizing and Chemoprotective Enzymes in Mice. Wael M. El-Sayed, **Tarek Aboul-Fadl**, and Michael R. Franklin. *Drug Development Research*, **71**, 313-322(2010).
30. Schiff Bases of Indoline-2,3-dione (Isatin) Derivatives and Nalidixic Acid Carbohydrazide, Synthesis, Antitubercular Activity and Pharmacophoric Model Building. **Tarek Aboul-Fadl**, Fayzah A. S. Bin-Jubair and Omima Aboul-Wafa. *Eur. J. Med. Chem.* **45**, 4578-4586 (2010).
31. Cell Cycle Disruption and Apoptotic Activity of 3-Aminothiazolo[3,2-*a*]benzimidazole-2-carbonitrile and its homologues. Abdelwareth A. O. Sarhan, Abdullah Al-Dhfyhan, Maha A. Al-Mozaini, Chaker N. Adra, and **Tarek Aboul-Fadl**. *Eur. J. Med. Chem.*, **45**, 2689-2694(2010).
32. Anti-Tubercular Activity of Isatin Derivatives. **Tarek Aboul-Fadl** and Fayzah A. S. Bin-Jubair. *Int. J. Res. Pharm. Sci.* **1**(2), 113-126 (2010).
33. New Sensitive HPLC Method for Evaluation of the Pharmacokinetics of New Amantadine Prodrugs as Hepatic Delivery Systems to Enhance its Activity against HCV. Ibrahim A. Darwish, **Tarek Aboul-Fadl**, Nasr Y. Khalil, Ashraf M. Mahmoud, Abdul-Rahman M. Al-Obaid. *Int. J. Res. Pharm. Sci.* **1**(2), 151-157 (2010).
34. Pharmacophoric Model Building for Antitubercular Activity of the Individual Schiff Bases of Small Combinatorial Library. Wesam S. Abdel-Aal, Hoda Y. Hassan, **Tarek Aboul-Fadl** and Adel F. Youssef, *Eur. J. Med. Chem.*, **45**, 1098-1106(2010).
35. Solution-Phase Synthesis of Small Schiff Bases Combinatorial Library with Potential Antitubercular Activity. Wesam S. Abdel-Aal, Hoda Y. Hassan, **Tarek Aboul-Fadl** and Adel F. Youssef, *Der Pharma Chemica*, **1**, 1-13(2009).
36. Selective Spectrophotometric and Fluorometric Method for the Determination of Amantadine Hydrochloride in Capsules and Plasma via Derivatization with Sodium 1,2- Naphthoquinone-4-Sulphonate. Ashraf M. Mahmoud, Nasr Y. Khalil, Ibrahim A. Darwish, **Tarek Aboul-Fadl**, *Intl. J. Anal. Chem.*, 1-9(2009).
37. A highly sensitive enzyme immunoassay for evaluation of 2_-deoxycytidine plasma level as a prognostic marker for breast cancer chemotherapy. Ibrahim A. Darwish, Ashraf M. Mahmoud, **Tarek Aboul-Fadl**, Abdul-Rahman A. Al-Majed, Nasr Y. Khalil. *Analytica Chimica Acta*, **632**, 266–271(2009).

38. Synthesis of a Peptide Nucleic Acid with a Novel 1-Methyl-6-mercaptopurine Base. **Tarek Aboul-Fadl**, Gopalan Rajeev Kallanthottathil and Arthur D. Broom. *J. Heterocyclic Chem.*, **45**,445-451(2008).
39. Pre- and post-initiation chemoprevention activity of 2-alkyl/aryl selenazolidine-4(R)-carboxylic acids against tobacco-derived nitrosamine (NNK)-induced lung tumors in the A/J mouse. M. R. Franklin, P. J. Moos, W. M. El-Sayed, **T. Aboul-Fadl**, J.C. Roberts. *Chem-Biol Interactions*, **168**, 211–220(2007).
40. Murine Hepatoma (Hepa1c1c7) Cells: A Responsive *In Vitro* System for Chemoprotective Enzyme Induction by Organoselenium Compounds. Wael M. El-Sayed, **Tarek Aboul-Fadl**, Jeanette C. Roberts, John G. Lamb and Michael R. Franklin. *Toxicology in Vitro*, **21**, 157-164(2007).
41. Antisense Oligonucleotide Technologies in Drug Discovery. **Tarek Aboul-Fadl**, *Expert Opin. Drug Discov.* **1**, 285-288(2006).
42. Sensitivity of *Escherichia coli* to L-selenaproline and other L-proline analogues in laboratory culture media and normal. human urine Charles Deutch, Maria Arballo, Latoya Cooks, Jenny Gomes, Tiara Williams, **Tarek Aboul-Fadl** and Jeanette Roberts, *Letters in Applied Microbiology* **43**, 392–398(2006).
43. Acute Effects of Novel Selenazolidines on Murine Chemoprotective Enzymes. Wael M. El-Sayed, **Tarek Aboul-Fadl**, John G. Lamb, Jeanette C. Roberts, and Michael R. Franklin. *Chemicobiological Interactions*, **162**, 31-42 (2006).
44. The Utility and Synthetic Uses of Mannich Reaction: An efficient Route for Synthesis of Thiadiazino-[1,3,5][3,2-a]Benzimidazoles. Abdel-Wareth A.O. Sarhan, Shams H. Abdel-Hafez, Hassan El-Sherif and **Tarek Aboul-Fadl**, *Synthetic Communications*, **36**, 987 - 996 (2006).
45. Effect of selenium-containing compounds on hepatic chemoprotective enzymes in mice. Wael M. El-Sayed, **Tarek Aboul-Fadl**, John G. Lamb, Jeanette C. Roberts, Michael R. Franklin, *Toxicology*, **220**, 179–188 (2006)
46. Synthesis of 5-Phenyl-1-(3-pyridyl)-1H-1,2,4-triazole-3-carboxylic Acid Derivatives of Potential Anti-inflammatory Activity. Safwat M. Rabea, Nawal A. El-Koussi, Hoda Y. Hassan, **Tarek Aboul-Fadl**, *Archiv der Pharmazie*, **339**, 32-40(2006).
47. Preparation of prodrugs and conjugates of thiol- and selenol-containing compounds. Michael R. Franklin, Jeanette Roberts, **Tarek Aboul-Fadl**, U.S. Pat. Appl. Publ. (2005), 20 pp
48. Selenium Derivatives as Cancer Preventive Agents. 'A Review Article'. **Tarek Aboul-Fadl**, *Current Medicinal Chemistry-Anti-Cancer Agents*, **5**, 637-52 (2005).
49. Antisense Oligonucleotides: The State of the Art 'A Review Article'. **Tarek Aboul-Fadl**, *Current Medicinal Chemistry*, **12**, 2193-2214(2005).
50. Synthesis and Antitubercular Activity of Some Mannich bases Derived from Isatin Isonicotinic acid hydrazone. Mostafa A. Hussein, **Tarek Aboul-Fadl** and Asmaa Hussein, *Bull. Pharm. Sci., Assiut University*, **28**, 131-136 (2005).
51. An Unusual "Senseless" 2'-5' Oligoribonucleotide with Potent Anti-HIV Activity. **Tarek Aboul-Fadl**, Vijai K. Agrawal, Robert W. Buckheit Jr. and Arthur D. Broom, *Nucleosides, Nucleotides & Nucleic Acids*, **23**, 545-554(2004).
52. Optical Isomers of 3-substituted-5-(2-carboxyethyl)-1,3,5- thiadiazin-2-thiones of Potential Antimicrobial Activity, Synthesis, and Solid State Stability. Mostafa A. Hussein, **Tarek Aboul-Fadl**, Mahrous Osman, Mohamed Hassan and Mohamed Hashem, *Egyptian J. of Biomedical Sciences.*, **16**, 194-209(2004).
53. Synthesis, Antitubercular Activity and Pharmacokinetic Studies of Some Schiff Bases Derived from 1- Alkylisatin and Isonicotinic Acid Hydrazide (INH). **Tarek Aboul-Fadl**, Fargany A. Mohammed and Ehssan A. Hassan, *Archives of Pharmacal Research*, **26**, 778-784 (2003).

54. 1,2-Dihydroisoquinoline-N-Acetic Acid Derivatives as New Carriers for Specific Brain Delivery I : Synthesis and Estimation of Oxidation Kinetics Using Multivariate Calibration Method, Sahar Mahmoud, **Tarek Aboul-Fadl**, Mahmoud Sheha, Hassan H. Farag and Abdel-Maboud I. Mouhamed, Arch. Pharm.Pharm. Med. Chem., **336**, 573-584 (2003).
55. 1,2-Dihydroisoquinoline-N-acetic acid Derivatives as New Carriers for Brain Specific Delivery II: Delivery of Phenethylamine as Model Drug, Sahar Mahmoud, Mahmoud Sheha, **Tarek Aboul-Fadl**, and Hassan H. Farag, Arch. Pharm.Pharm. Med. Chem., **336**, 526-531(2003).
56. Synthesis, Degradation kinetics and *In-vitro* Antimicrobial Activity of Tetrahydro-2H-1,3,5-thiadiazine-2-thione Derivatives of Some β -Amino Acids, **Tarek Aboul-Fadl** and Abdel-Raouf Khallil, Arzneim-Forsch./Drug Res., **53**(7), 526-531(2003).
57. Tetrahydro-2H-1,3,5- thiadiazin-2-thione Derivatives of The optical Isomers of Phenylalanine, Synthesis, Comparative Stability Study and Antifungal Activity, **Tarek Aboul-Fadl**, and Mahrous Osman, Sci. Pharm., **70**, 359-378(2002).
58. New 2H-Tetrahydro-1,3,5-thiadiazine-2-thiones Incorporating Glycine and Glycinamide as Potential Antifungal Agents, **Tarek Aboul-Fadl**, Mostafa A. Hussein, Abdel-Nasser El-Shorbagi, and Abdel-Raouf Khallil, Arch. Pharm.Pharm. Med. Chem., **335**, 438-442(2002).
59. Kinetics of solid state stability of glycine derivatives as a model for peptides using differential scanning calorimetry, Mostafa I. Abd-Elrahman, Mahrous O. Ahmed, Sayed M. Ahmed, **Tarek Aboul-Fadl** and A.El-Shorbagi, Biophysical chemistry, **19**, 113-20(2002).
60. Di- and Trisubstituted Pyrazolo[1,5-a]pyridine Derivatives: Synthesis, Dopamine Receptor Binding and Ligand Efficacy. Stefan Löber, **Tarek Aboul-Fadl**, Harald Hübner and Peter Gmeiner, Bioorganic and Medicinal Chemistry Letters, **12**, 633-636(2002).
61. New Paeonilactone-A-Adducts Formed by Incubation of Paeoniflorin with *Lactobacillus brevis* in Presence of Arylthiols, Atef A. Abdel-Hafez, Meselhy R. Meselhy, Norio Nakamura, Masao Hattori, Mahmoud A. El-Gendy, Nadia M. Mahfouz and **Tarek A. Mohamed**, Chem. Pharm. Bull., **49**, 918-920(2001).
62. Antigiardial Activity of Metronidazole Twin Ester Prodrugs. Ahmed K. Dyab and **Tarek Aboul-Fadl**, Zagazig University Medical Journal, **VII**(5), 1268-1275(2001).
63. Investigation of Alkylating, Antineoplastic and Anti-HIV Potentials of the Chalcones; 2-(3-Arylpropenoyl)benzimidazole and Their Corresponding N1-Methyl Derivatives. **Tarek Aboul-Fadl**, Abdel-Nasser El-Shorbagi, Zeinab A. Hozien and Abdel-Wareth A.O. Sarhan, Bollettino Chimico Farmaceutico, **139**, 228-234(2000).
64. Effective and Variable Functionalization of Pyrazolo[1,5-a]pyridines Involving Palladium-Catalyzed Coupling Reactions. **Tarek Aboul-Fadl**, Stefan Löber and Peter Gmeiner, Synthesis, **12**, 1727-1732 (2000).
65. Cyclic amide derivatives as potential prodrugs: N-hydroxymethyl-succinimide-/isatin esters of some NSAIDs as chemical delivery system with improved therapeutic index, F.A. Omar, N. M. Mahfouz and **T. Aboul-Fadl**, Eur. J. Med. Chem., **34**, 551-562(1999).
66. Anticonvulsant Activity of Paeonimetabolin-I Adducts Obtained by Incubation of Paeoniflorin and Thiol Compounds with *Lactobacillus brevis*, A.A. Abdel-Hafez, M. R. Meselhy, N. Nakamura, M. Hattori, H. Watanabe, Y. Murakami. M. A. El-Gendy, N. M. Mahfouz and **T. A. Mohamed**, Biol. Pharm. Bull., **22**, 491-497(1999).
67. Tetrahydro-2H-1,3,5-thiadiazin-5-(4-pyridylcarboxamide)-2-thione Derivatives as prodrugs for Isoniazid, Synthesis, Investigations and *In Vitro* Antituberculous Activity, **T. Aboul-Fadl** and K. Hassanin, Pharmazie, **54**, 244-247(1999).
68. Chitosan Conjugates of Ibuprofen and Flurbiprofen: Synthesis, Characterization and *in vitro* Stability, **T. Aboul-Fadl**, M. M. Sheha and S. Khider, Sci. Pharm., **67**, 27-41(1999).

69. Metronidazole Twin Ester Prodrugs II : Non Identical Twin Esters of Metronidazole and Some Antiprotozoal Halogenated Hydroxyquinoline Derivatives, **T. Aboul-Fadl** and N. M. Mahfouz, *Sci. Pharm.*, **66**, 309-324(1998).
70. Esters Twin Drugs of Metronidazole : Synthesis, Physicochemical properties, Kinetic studies and Antigardial activity, N. M. Mahfouz, **T. Aboul-Fadl** and A. K. Diab, *Eur. J. Med. Chem.*, **33**, 675-683(1998).
71. Effects of Paeoniflorin Derivatives on the Scopolamine-Induced Amnesia Using a Passive Avoidance Task in Mice; Structure-Activity Relationship, Abdel-Hafez, M. R. Meselhy, N. Nakamura, M. Hattori, H. Watanabe, Y. Murakami, M. A. El-Gendy, N. M. Mahfouz and **T. A. Mohamed**, *Biol. Pharm.Bull.*, **21**, 1174-1179(1998).
72. Paracetamol (Acetaminophen) Esters of Some Non-steroidal Anti-inflammatory Carboxylic acids Drugs as Mutual Prodrugs with Improved Therapeutic Index., **T.A. Fadl** and F. A. Omar, *Inflammopharmacology*, **6**, 143-157(1998).
73. Potent Anticonvulsant Paeonimetabolin-I Derivatives Obtained by Incubation of Paeoniflorin and Sulfhydryl Compounds With Lactobacillus Brevis, Abdel-Hafez, M. R. Meselhy, N. Nakamura, M. Hattori, H. Watanabe, **T. A. Mohamed**, N. M. Mahfouz and M. A. El-Gendy, *Chem.Pharm. Bull.*, **46**,1486-1487(1998).
74. New Carriers for Representative Peptide Drugs, **T. Aboul-Fadl** and A. El-Shorbagi, *Arch. Pharm.Pharm. Med. Chem*, **330**, 327- 332(1997).
75. Steric Parameters in PLE Catalyzed Hydrolysis of N⁴-substituted Cytarabine Esters Prodrugs, T. Kawaguchi, A.F.Youssef, **T.Aboul-Fadl**, F.A.Omar, H.H.Farag, and T.Hasegawa, *Pharmazie*, **51**, 717-719(1996).
76. New Prodrug Approach for Amino Acids and Amino-Acid-Like Drugs, **T.Aboul-Fadl** and A. El-Shorbagi, *Eur. J. Med. Chem.*,**31**,165-169(1996).
77. Synthesis and *In Vitro* Investigation of Nalidixic Acid Amides of Amino Acid Esters as Prodrugs, **T. Aboul-Fadl** and E. A. Fouad, *Pharmazie*, **51**, 30-33(1996).
78. Synthesis and Investigation of N⁴-substituted Cytarabine Derivatives as Prodrugs, **T.A.Fadl**, T.Hasegawa, A.F.Youssef, H.H.Farag, F.A.Omar and T.Kawaguchi, *Pharmazie*, **50**, 382-387(1995).
79. ¹HNMR and chelating properties of 1,5-dimethyl-N-substituted-1H-pyrazole-3- carboxamides and 1,3-dimethyl-N-substituted-1H-pyrazole-5-carboxamides, **T.Abo-El-Fadl**, A. F. Youssef and A. N. Ahmed, *Pharmazie*, **48**,117-120(1993).
80. ¹HNMR of Pyrazoles : effect of interaction of carbamoyl group with adjacent centers on the chemical shifts of concerned protons, **T.A. Mohamed**, A. F. Youssef and A. N. Ahmed, *Bull. Pharm. Sci., Assiut University*, **15**, 100-105(1992).
81. Synthesis and Biological activity of certain 1,3- and 1,5-dimethyl-N-substituted pyrazole carboxamides, **T.A. Fadl**, A. F. Youssef, A. N. Ahmed and H. I. El-Bitar, *Bull. Pharm. Sci., Assiut University*, **13**, 145-158(1990).

4. عروض المؤتمرات

1. Thiadiazine-2-thione Derivatives as New Carrier Systems for Isothiocyanates and Dithiocarbamic acid with Potential Anticancer Activities, Tarek Aboul-Fadl, 10th Edition of Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2023) Online Conference, September 14-15, 2023.
2. Thiadiazine-2-thione derivatives as new cell- cycle inhibitors, Tarek Aboul-Fadl, 8th Edition of Global Conference on Pharmaceutics and Novel Drug Delivery Systems (Pharma 2023) Online Conference, March 14-15, 2023. <https://magnusconferences.com/pharmaceutical-sciences/speaker/tarek-aboul-fadl>
3. Prodrugs of non-steroidal anti-inflammatory drugs (NSAIDs) and Amino acid esters as novel non-cyclooxygenase inhibitors for colorectal cancer chemoprevention, Tarek Aboul-

- Fadl, 7th Edition of Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2022) Online Conference, September 8-10, 2022. <https://pharmaceuticsconference.com/speakers/2022>
4. Structure Based Design of Novel Azine Linked Hybrids of 2-Indolinone- Thiazolodine Scaffold as Potential Quorum Sensing Inhibitors for Fighting Antimicrobial Resistance, Wesam S. Qayed, Mostafa A. Hassan, Ahmed Megahed Abouwarda, Yasser Musa Ibrahim, **Tarek Aboul-Fadl**, International Conference and Expo on Applied Microbiology (ICAM 2022) Online Conference, June 17-18, 2022. <https://applied-microbiology.magnusconferences.com/speakers/2022/>
 5. Novel Spiro Hybrids of 2-indolinone and Thiazolodinone Scaffolds as Cell Cycle Checkpoints' Pathways Regulators with potential anticancer activity, Ahmed K. Hamdy, Hend A.A. AbdEl-wahab, Wesam S Qayed, Wael M. El-Sayed, **Tarek Aboul-Fadl**, 6th Edition of Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PHARMACEUTICS 2022) Online Conference, June 13-14, 2022. <https://pharma.magnusconferences.com/program/scientific-program/2022/>
 6. Novel Azine Linked Hybrids of 2-indolinone and Thiazolodinone Scaffolds as CDK2 inhibitors with potential anticancer activity, Wesam S. Qayed, Mostafa A. Hassan, Wael M. El-Sayed and **Tarek Aboul-Fadl**, 5th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (Pharma 2022) Online Conference, March 28-30, 2022. <https://magnusconferences.com/pharmaceutical-sciences/speaker/tarek-aboul-fadl>
 7. Novel 2-Indolinone Based derivatives Targeting Cell Cycle Checkpoint's Proteins as Potential Anticancer Agents, **Tarek Aboul-Fadl**, Mostafa A. Hassan, Wesam S. Quayed and Wael M. El-Sayed, 2nd global virtual Conference on Pharmaceutical Sciences and Drug Development (World Pharma 2021), Oregon/USA, August 9th, 2021. (*On line*)
 8. Design and synthesis of some 1,3,5-tri-substituted oxindole derivatives as potential CDK inhibitors, S. Mansour, Hend A. A. Abd El-Wahab, Ahmed M. Ali, **Tarek Aboul-Fadl**, Assiut University 12th International Pharmaceutical Sciences Conference, Assiut - Egypt. November 4-5, 2020. P.102
 9. Novel 3-(Benzylidene)indolin-2-one Derivatives as Cyclin-Dependent Kinase (CDK) Inhibitors with Potential Anticancer Activity, Hany S. Mansour, Hend A. Abdel-Moneim, Ahmed M. Ali, **Tarek Aboul-Fadl**, 18th Austrian Chemistry Days, Linz – Austria, September 24 – 27, 2019.
 10. Novel Non-Cyclooxygenase Inhibitory Derivatives of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for Colorectal Cancer Chemoprevention, **Tarek Aboul-Fadl**. 11th breast- Gynecological & Immunooncology International Cancer Conference (BGICC 2019), Cairo, Egypt, January 17-18, 2019.
 11. Novel indole-2,3-dione (isatin) derivatives as CDK2 inhibitors with potential anticancer activity, Mohamed A. Yousef, Ahmed M. Ali, Wael M. El-Sayed, Hassan H. A. Farag, **Tarek Aboul-Fadl**. 2nd International Conference of the Faculty of Pharmacy, Ain Shams University (2nd ICPASU), Cairo, Egypt, November 13-15, 2018.
 12. Utilization of microwave technology for simple, efficient and enhanced synthesis of spiro-thiazoldinediones with potential antimycobacterium activity, Ahmed K. Hamdy, Hend A.A. AbdEl-wahab, Wesam S Qayed , **Tarek Aboul-Fadl**. 2nd International Conference of the Faculty of Pharmacy, Ain Shams University (2nd ICPASU), Cairo, Egypt, November 13-15, 2018.
 13. Modified Lidocaine Derivatives as a Potential Inhibitors of Eosinophils, **Tarek Aboul-Fadl**, Ahmed S. M. Aboraia, Abu-Baker M. Abdel-Aal, Mohammed K. Abdel-Hamid, Wesam S. Abdel-Aal, Ola M. F. Abou-Ghadir, Mariam E. I. Abdel-Rasoul, Rana M. Ibrahim, Mostafa A. Hassan, Noha G. M. Fekry, Hend A.A. Abd El-Wahab and Adel F. Youssef, 2nd International Congress and Exhibition on Pharmacy (Pharmacy-2018), Paris, France, August 20-21, 2018.
 14. Novel synthetic inhibitors of eosinophils with potential anti-asthmatic activity, **Tarek Aboul-Fadl**, 4th International Congress on Drug Discovery, Designing and Development, Chicago, Illinois, USA, November 2-3, 2017.

15. Synthesis Of New 4-Aminosalicylates-, Triazole- and Hydrazone-Based Conjugates With Potential Anti-Tubercular Activity. Hajjaj H. M. Abdu-Allah, Bahaa G. M. Youssif, Mustafa H. Abd-Elrhman, Mohammed K. Abdel-Hamid, **Tarek Aboul-Fadl**, and D. Sriram. 52nd International Conference on Medicinal Chemistry (RICT 2016), Caen-France, July 6 -8, 2016.
16. Efficient Schiff Bases of Indoline-2,3-dione (Isatin) Derivatives against Single Resistant Strains of *Mycobacterium tuberculosis*. **Tarek Aboul-Fadl**, Adel F. Yousef and Mohammed K. Abdel-Hamid, 246rd American Chemical Society meeting, Indianapolis, Indiana -USA, September 8-14, 2013.
17. Novel amino acid derivatives of naproxen for colon cancer chemoprevention. **Tarek Aboul-Fadl**, Suliman S. Al-Hamad, Mohammed K. Abdel-Hamid, Hatem A. Abdel-Aziz, Abdel-Rahman M. Al-Obaid, Jason D. Whitt, Bernard D. Gary, Adam B. Keeton and Gary A. Piazza. 243rd American Chemical Society meeting, San Diego, California -USA, March 25-29, 2012.
18. Schiff Bases of Indoline-2,3-dione As Potential Novel Inhibitors of *Mycobacterium tuberculosis* (Mtb) DNA Gyrase. **Tarek Aboul-Fadl**, Hatem A. Abdel-Aziz, Telal Al-Samani, Pervez Ahmad, Adnan Khadi, Ibrahim Darwish, Mohammed K. Abdel-Hamid, Jane Thanassi and Michael J. Pucci. 47th International Conference on Medicinal Chemistry (RICT 2011), Lyon-France, July 6 -8, 2011.
19. Design and Synthesis of substituted Nicotinic Acid Hydrazones With Potential Antiproliferative Activity. **Tarek Aboul-Fadl**, Hatem A. Abdel-Aziz, Abdul-Rahman M. Al-Obaid, Abdullah Al-Dhfyhan and Alessandro Contini. The 66th Northwest Regional Meeting of The American Chemical Society (NORM 2011), Portland, Oregon-USA, June 26 -29, 2011.
20. Design and Synthesis of a Combinatorial Library of Indoline-2,3-dione Schiff bases with Potential Anti-tubercular Activity. **Tarek Aboul-Fadl**, Hatem A. Abdul-Khader, Adnan Khadi, Ibrahim Darwish, Telal Al-Samani, Pervez Ahmad, Ahmed Bari and Sahal Al-Hajoj. 46th International Conference on Medicinal Chemistry (RICT 2010), Reims-France, June 30 -July 2, 2010.
21. Schiff Bases of Indol-2,3-dione (Isatin) Derivatives and Nalidixic Acid Hydrazidewith Potential Antitubercular Activity. Fayzah A. S. Bint-Jubair, Omima Aboul-Wafa and Tarek Aboul-Fadl. The 8th Saudi International Pharmaceutical Conference and Exhibition, Riyadh-Saudi Arabia, April 26-28, 2010.
22. Antimicrobial and Estrogenic Activity of Ferutinin and Selected Semi-Synthetic Analogs. Ahmed Galal, Safwat Ahmed, Ehab A. Abourashed, Desmond Slade, Waseem Gul, Shabana Khan, **Tarek Aboul-Fadl** and Mahmoud A. ElSohly, The 50th Anniversary Meeting of the American Society of Pharmacognosy, Honolulu, HI-USA, June 27-July 1, 2009.
23. Evaluation of The Pharmacokinetic of New Amantadine Prodrugs As Hepatic Delivery Systems to Enhance Its Activity Against HCV by A New HPLC Method. **Tarek Aboul-Fadl** , Ashraf M. Mahmoud, Nasr Y. Khalil, Ibrahim A. Darwish and Abdul-Rahman Al-Obaid. 237th American Chemical Society meeting, Salt Lake City, Utah-USA, March 22-26, 2009.
24. Preparation, Antimicrobial and Estrogenic Activity of Ferutinin and Selected Analogs. Ahmed Galal, Safwat Ahmed, Ehab A. Abourashed, Desmond Slade, Waseem Gul, Shabana Khan, **Tarek Aboul-Fadl** and Mahmoud A. ElSohly, The annual meeting of the National Center for Natural Products Research of the University of Mississippi, University of Mississippi-USA, January 2009.
25. Selenium Derivatives as a Cancer Preventive Agents. **T. Aboul-Fadl**, 2nd World Conference on Magic Bullets (Ehrlich II). Nürnberg, Germany, October 3 - 5, 2008.
26. Regulation of ATP-binding cassette (Abc) transporters by organoselenium compounds. Dorinda D. Arch. Wael M. El-Sayed, **Tarek Aboul-Fadl**, Jeanette C. Roberts and Michael R. Franklin. San Diego, California, USA, April 2008.
27. Chemoprevention in mice by 2-alkyl/aryl selenazolidine-4(R)-carboxylic acids. M.R. Franklin, J.C. Roberts, W.M. El-Sayed, **T. Aboul-Fadl**, T. Schofield, J.E. Constance and J.G. Lamb. The 46th Annual Meeting (SOT), Charlotte, NC-USA, March 2007. Abstract 609, Toxicological Sciences p126S.

28. Design, Synthesis and Antitubercular Evaluation of Small Schiff Base Combinatorial Library. Wesam S. Abd-el Aal, Hoda Y. Hassan, **Tarek Aboul-Fadl**, Adel F. Youssef. The 7th International Saudi Pharmaceutical Conference. Riyadh-Saudi Arabia, March 19-21 2007.
29. Effects of acute exposure of selenazolidines prodrugs of L-selenocysteine on chemoprotective enzymes in mice and Hepal1c7 cells. Wael M. El-Sayed, **Tarek Aboul-Fadl**, John G. Lamb, Jeanette C. Roberts and Michael R. Franklin. The 45th Annual Meeting of the Society of Toxicology (SOT), San Diego, California-USA, March 5-9, 2006.
30. The biological effects of selenocysteine prodrugs. Wael M. El-Sayed, **Tarek Aboul-Fadl**, John G. Lamb, Jeanette C. Roberts and Michael R. Franklin, Annual Bioscience Symposium, University of Utah, Salt Lake City, Utah-USA, September 9, 2005.
31. Uptake of L-Selenaproline by the L-Cystine Transport System in *Escherichia coli*, C. E. Deutch, M. E. Arballo, L. N. Cooks, J. M. Gomes, T. M. Williams, **T. Aboul-Fadl**, and J. C. Roberts. 105th General Meeting of the American Society for Microbiology, Atlanta, Georgia, USA, June 5-9, 2005.
33. Hepatic effects of novel selenazolidine prodrugs of selenocysteine developed as potential cancer chemopreventive agents, **Tarek Aboul-Fadl**, Wael M. El-Sayed, Tenley Schofield, Jonathan Constance, John G. Lamb, Jeanette C. Roberts, and Michael R. Franklin. [229th ACS National Meeting, San Diego, California, USA, March 13-17, 2005.](#)
34. Phase II Drug Metabolizing Enzyme mRNA Changes by Novel Selenazolidine Prodrugs of Selenocysteine in Mice, Wael M. El-Sayed, **Tarek Aboul-Fadl**, Ronald B. McEwen, Tenley Schofield, John G. Lamb, Jeanette C. Roberts and Michael R. Franklin, The 22nd Annual Meeting of the Mountain West Society of Toxicology (MWSOT), Park City – Utah, USA. September 9-10, 2004. P.18
35. Synthesis of 5-Phenyl-1-(Pyridyl)-1H-1,2,4-triazole-3-Carboxylic Acid Derivatives of potential Antiinflammatory Activity, Safwat M. Rabea, **Tarek Aboul-Fadl**, Nawal A. El-Koussi and Hoda Y. Hassan, Assiut University 4th Pharmaceutical Sciences Conference, Assiut - Egypt. March 6-7, 2004. P.122
36. Synthesis and Antitubercular Activity of some Schiff Bases Derived from Mannich Bases of Isatin and Isonicotinic Acid Hydrazide (INH), Mostafa Hussein, **Tarek Aboul-Fadl** and Asmaa Abdel-Nasser, Polish-Austrian-German-Hungarian-Italian Joint Meeting on Medicinal Chemistry, KrakÓw, Poland 15-18 October 2003.
37. Unusual “Senseless” 2’-5’ Oligoribonucleotide with a Potent Anti-HIV Activity, **Tarek Aboul-Fadl**, Vijai Agrawal, Robert W. Buckheit Jr and Arthur D. Broom, The 1st International Congress of Pharmaceutical and Drug Industries Division, National Research Center, Cairo-Egypt, March 24-26(2003).p.118
38. Synthesis of a Peptide Nucleic Acid with a Novel 1-Methyl-6-thiopurine Base, **Tarek Aboul-Fadl**, K.G. Rajeev and A.D. Broom, 223 ACS meeting, Orlando, Florida-USA, April 6-11 (2002).
39. 1,2-Dihydroisoquinoline Derivatives as New Carrier for Brain Specific Delivery, Sahar M. Mohamoud, Mahmoud M. Sheha, **Tarek Aboul-Fadl** and Hassan H. Farag, Assiut University Third Pharmaceutical Sciences Conference, Assiut-Egypt, March 5-6 (2002)
40. Synthesis of New Optically Active Thiadiazine-2-thione Derivatives as Antifungal Agents, M.A. Hussein and **T. Aboul-Fadl**, 8th IBN SINA International Conference on Pure and Applied Heterocyclic Chemistry, Luxor-Egypt, Feb. 16-19 (2002).
41. Synthesis and Antifungal Activity of Some New 3,5-Disubstituted Tetrahydro-2H-1,3,5-Thiadiazine-2-Thione, **T. Aboul-Fadl**, M.A. Hussein and A. A. El-Shorbaji, XXVII Conference of Egyptian Pharmaceutical Society, Cairo - Egypt, January 2-4 (2001), P.57.

42. Synthesis of 7-Substituted 3-[4(4-Chlorophenyl)-Piperazin-1-ylmethyl]-Pyrazolo[1,5-a]Pyridine Derivatives as Potential D4-Receptor Ligands, **T. Aboul-Fadl**, S. Löber and P. Gmeiner, XXVII Conference of Egyptian Pharmaceutical Society, Cairo - Egypt, January 2-4(2001), P. 56.
43. Chitosan Conjugates of Ibuprofen and Flurbiprofen: Synthesis, Characterization and in vitro Stability, **T. Aboul-Fadl**, M. M. Sheha and S. Khider, XXVI Conference of Egyptian Pharmaceutical Society, Cairo- Egypt, December 8-10(1998), p. 31.
44. Flow injection analysis of amino acids using Cu(II) oxide as a packed reactor for ultraviolet detection, S. Emara and **T. Aboul-Fadl**, Fourth European Congress of Pharmaceutical Sciences, Milan-Italy, September 11-13(1998).
45. Cyclic amide derivatives as potential prodrugs: N-hydroxymethyl-succinimide-/isatin esters of some NSAIDs as chemical delivery system with improved therapeutic index, F. A. Omar, N. M. Mahfouz and **T. Aboul-Fadl**, XIV Scientific Meeting of the Austrian Pharmaceutical Society, Graz - Austria, June 11-13(1998), p. S85.
46. A Structurally Simplified Analogue of the Antibiotic Heptelidic Acid With a Five Membered Carbocyclic Ring, **T. Aboul-Fadl**, W. Fleischhacker and E. Urban, XIV Scientific Meeting of the Austrian Pharmaceutical Society, Graz -Austria, June 11-13(1998), p. S15.
47. Acetaminophen Esters of Some Non-steroidal Antiinflammatory Drugs as Mutual Prodrugs with Improved Therapeutic Index, **T. A. Fadl** and F. A. Omar, Assiut University First International Pharmaceutical Sciences Conference, Faculty of Pharmacy, Assiut-Egypt, March 4-5(1998), p. 3.
48. Metronidazole Twin Esters Prodrugs II : Non Identical Twin Esters of Metronidazole and Some Antiprotozoal Halogenated Hydroxyquinoline Derivatives, **T. Aboul-Fadl**, N. M. Mahfouz and A. K. Diab, Assiut University First International Pharmaceutical Sciences Conference, Faculty of Pharmacy, Assiut-Egypt, March 4-5(1998), p. 1.
49. Modifications of Paeoniflorin and Paeonimetabolin I by Chemical and Biochemical Means, Abdel-Hafez, M. R. Meselhy, N. Nakamura, M. Hattori, H. Watanabe, **T. A. Mohamed**, N. M. Mahfouz and M. A. El-Gendy, International Symposium on Natural Medicines, Kyoto - Japan, October 28 -30(1997), p. 3P-032.
50. Tetrahydro-2H-1,3,5-thiadiazin-2-thione derivatives as new carriers for peptide drugs, **T. Aboul-Fadl** and A. El-Shorbagi, XXV Conference of Egyptian Pharmaceutical Society, Cairo- Egypt, December 24-26(1996), p. 68.
51. Synthesis and Investigation of the Alkylating Potential of 2-(3-Arylpropen-oyl)benzimidazole and their Corresponding N1-methyl Derivatives, **T. Aboul-Fadl**, A. El-Shorbagi, Z. Hozein and A. Sarhan, Al-Azhar First International Conference on Recent Advances in Pharmaceutical Technology and Biological Sciences, Cairo - Egypt, December 19-21(1995), p. 95.
52. Synthesis, Hydrolysis Kinetics, Lipophilicity, and Biological Activity of N⁴-(3-Alkoxy and Benzyloxycarbonylpropionyl)-Ara-C Prodrugs, **T.A.Fadl**, T.Hasegawa, A.F.Youssef, H.H.Farag, F.A.Omar and T.Kawaguchi, World congress of Pharmacy and Pharmaceutical Sciences "FIP'93", Tokyo, Japan, September 5-10(1993), Abstract No. S098.
53. ¹H-NMR and chelating properties of 1,5-dimethyl-N-substituted -1H- pyrazole-3-carboxamides and 1,3-dimethyl-N-substituted-1H- pyrazole-5-carboxamides, **T.A. Fadl**, A. F. Youssef, A. N. Ahmed, 3rd IBN SINA Symposium on Heterocyclic Chemistry, Aswan, Egypt, January 28-31(1991), p. 126.